Concord Biotech Ltd. · NSE:CONCORDBIO
Concord Biotech — Q4 FY2026 Earnings Presentation
30 slides from Concord Biotech's earnings presentation, May 30, 2026
Slide 1: Exchange filing cover letter
CONCORD BIOTECH LIMITED B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat. Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440 Email ID: complianceofficer@concordbiotech.com ------------------------------------------------------
Slide 2: Concord Biotech Limited Investor Presentation – May 2026
CONCORD BIOTECH Concord Biotech Limited Investor Presentation – May 2026
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Concord Biotech Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secur
Slide 4: Q4 & FY26 Key Financial Highlights
Q4 & FY26 Key Financial Highlights
Slide 5: FY26 Key Highlights – Building the Next Phase of Growth
FY26 Key Highlights – Building the Next Phase of Growth 1 2 3 4 5 Regulatory Injectables Facility CDMO & Second Source Building Global Investing for Future Strengthening Scaling Up Opportunities Commercial Footprint Growth Platforms • Commencement of supplies of Concord • Stellon Biotech obtained al
Slide 6: Challenges encountered during FY26
Challenges encountered during FY26 Delay in supply to EU on US Procurement Global Tariff & Trade Middle East Headwinds US Veterans Affairs account of delay in Pattern Shift Uncertainty On account of geopolitical Tender Delay Written Confirmation from CDSCO tensions Delay in receipt of Customers adop
Slide 7: Q4 & FY26 Consolidated Financial Highlights
Q4 & FY26 Consolidated Financial Highlights Revenue (Rs. in Crs) EBITDA (Rs. in Crs) PAT (Rs. in Crs) 1,200.1 506.3 371.6 1,054.9 367.4 259.2 429.9 190.4 140.4 326.1 118.5 88.5 Q4FY25 Q4FY26 FY25 FY26 Q4FY25 Q4FY26 FY25 FY26 Q4FY25 Q4FY26 FY25 FY26 Gross Profit Margin (%) EBIDTA Margin (%) PAT Margi
Slide 8: Q4 & FY26 Segment wise Revenue Split
Q4 & FY26 Segment wise Revenue Split API Revenue (Rs. in Crs) Formulation Revenue (Rs. in Crs) Total Revenue (Rs. in Crs) 940.1 260.0 1,200.1 828.8 226.1 1,054.9 362.4 429.9 263.8 67.5 62.3 326.1 Q4FY25 Q4FY26 FY25 FY26 Q4FY25 Q4FY26 FY25 FY26 Q4FY25 Q4FY26 FY25 FY26 API : Formulation API : Formulat
Slide 9: Q4 & FY26 Geography wise Revenue Split
Q4 & FY26 Geography wise Revenue Split Domestic Revenue (Rs. in Crs) Exports Revenue (Rs. in Crs) Total Revenue (Rs. in Crs) 661.8 538.3 1,200.1 491.3 1,054.9 563.6 239.4 190.5 429.9 168.7 157.4 326.1 Q4FY25 Q4FY26 FY25 FY26 Q4FY25 Q4FY26 FY25 FY26 Q4FY25 Q4FY26 FY25 FY26 Domestic : Export Domestic
Slide 10: Management Commentary
Management Commentary Commenting on the Q4 & FY26 performance of the company Mr. Ankur Vaid, Joint Managing Director & Chief Executive Officer for Concord Biotech Limited said, “FY26 was a challenging year for the Company, with revenue impacted by delays in customer procurement decisions, uncertaint
Slide 11: Q4 & FY26 Consolidated Profit & Loss Account
Q4 & FY26 Consolidated Profit & Loss Account Profit and Loss (Rs. in Crs) Q4FY26 Q4FY25 YoY / Bps FY26 FY25 YoY / Bps Revenue from Operations 326.1 429.9 -24% 1,054.9 1,200.1 -12% Cost of Goods Sold 85.8 128.5 245.7 305.5 Gross Profit 240.3 301.4 -20% 809.2 894.6 -10% Gross Profit Margin 73.7% 70.1%
Slide 12: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (in Rs. Crs) Mar-26 Mar-25 Equity & Liabilities (in Rs. Crs) Mar-26 Mar-25 Non - Current Assets 984.6 899.0 Total Equity 2,015.1 1,812.7 Property Plant & Equipment's 785.7 791.8 Share Capital 10.5 10.5 CWIP 78.2 50.1 Other Equity 2,006.6 1,802.3 Intangible assets 0.
Slide 13: Abridged Cashflow Statement
Abridged Cashflow Statement Particulars (in Rs. Crs) FY26 FY25 Net Profit Before Tax 344.6 494.6 Adjustments for: Non -Cash Items / Other Investment or Financial Items 36.5 30.1 Operating profit before working capital changes 381.2 524.7 Changes in working capital -13.9 -170.8 Cash generated from Op
Slide 14: Company Overview
Company Overview
Slide 15: Concord Biotech at a Glance
Concord Biotech at a Glance Concord Biotech Limited is a R&D driven biopharma Company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. Key Highlights Expertise in ✓ Expertise in fermentation-based API manufacturing wit
Slide 16: Driving Innovation Through Our Expertise
Driving Innovation Through Our Expertise Fermentation Expertise Through our strong fermentation capabilities, we produce high-quality APIs, setting us apart in biotechnology and ensuring superior efficacy in medicines Mission Focus Dedicated to deliver high-quality product that enhance human health,
Slide 17: API Business Overview
API Business Overview API Overview One of the leading global developers and Focus on Niche Fermentation API’s with Diversified Product Portfolio of API’s including manufacturers of Fermentation-based APIs backward integration to Key Starting Material Immuno-suppressant, Oncology, Anti- Infectives &
Slide 18: Formulation Business Overview
Formulation Business Overview Formulation Overview Commercialization of Formulations business in Operate through B2B model across regulated Oral Solid Dosages (tablets, capsules and oral suspension) 2016 to capitalize on the benefits of backward and emerging markets Injectables (Liquid Vials, Dry Po
Slide 19: Trusted CDMO partner for Fermentation & Semi-Synthetic API’s
Trusted CDMO partner for Fermentation & Semi-Synthetic API’s CDMO Overview Prioritizes innovation, backed by a DSIR- Expertise in fermentation technology and strong Provide contract research and manufacturing R&D infrastructure enable us to undertake complex certified R&D facility with a team of 180
Slide 20: Pushing Boundaries through Manufacturing Capabilities
Pushing Boundaries through Manufacturing Capabilities Unit I (API) – Dholka, Gujarat Unit II (Formulations) – Valthera, Gujarat FY2000 Operations commenced FY2016 Operations commenced 1,12,302 sq.m. Spread across 94,826 sq.m. Spread across 450 m3 Installed capacity 802Mn Units Installed capacity Uni
Slide 21: Pioneering R&D Capabilities
Pioneering R&D Capabilities R&D Initiatives: State-of-the-Art Facilities: Where Ideas Materialise 180 7/5 R&D Employee Approved ANDA/ API R&DLab Strength Finished Products Cost Improvement • Specialized capabilities for isolation of strains, mutation, and passive selection of microbial strains, as w
Slide 22: DMF Filings Across Geographies
DMF Fillings Across Geographies Molecules US EU Canada Japan China Tacrolimus ✓ ✓ ✓ ✓ ✓ Mycophenolate Mofetil ✓ ✓ ✓ ✓ ✓ Suppressants Immuno- Mycophenolate Sodium ✓ ✓ ✓ ✓ Cyclosporine ✓ ✓ ✓ ✓ ✓ Sirolimus ✓ ✓ ✓ ✓ Pimecrolimus ✓ Voclosporin ✓ Temsirolimus ✓ ✓ Everolimus ✓ ✓ ✓ ✓ Oncology Romidepsin ✓ ✓
Slide 23: Wide Range of Formulation Product Portfolio for Overseas Markets
Wide Range of Formulation Product Portfolio for Overseas Markets Regulated Markets Emerging Markets Product Name ANDA Approval Product Name Mycophenolate Mofetil Capsules Mycophenolate Mofetil Capsules Mycophenolate Mofetil Tablets Mycophenolic Acid DR Tablets USP Mycophenolate Mofetil Suspension My
Slide 24: Diversified Customer Base
Diversified Customer Base 70+ 250+ Countries Customers Reducing Customer Concentration % Contribution from Top 10 Customers 37.6% FY26 37.8% FY25 42.0% FY24 FY23 44.3% Worldwide Presence Tailored Distribution Models FY22 47.7% Collaborative Partnerships 23
Slide 25: Paving the Way for Sustainability
Paving the Way for Sustainability Our Vision for Sustainability The Path of Sustainability Sustainable Manufacturing Research & Development Efficient Resource Management Global Green Leadership Constant Improvement & Adaptation Environmental Conservation Awarded Bronze Medal by EcoVadis Our Initiati
Slide 26: Key Business Differentiators
Key Business Differentiators
Slide 27: End-to-End Expertise in Complex Fermentation Value Chain
End-to-End Expertise in Complex Fermentation Value Chain Overview of Integrated Platform Leadership Position 1,250 M3 Leadership position for select molecules Fermentation Capacity across two in global markets API facilities R&D Patents 01 02 03 04 Key Starting Material API Manufacturing Over 2 Deca
Slide 28: Constructing Formidable Barriers to Entry
Constructing Formidable Barriers to Entry Significant Capital Intensive Operational Complex Process & Infrastructural Requirements Long gestation Period Entry Barriers Technical Expertise Requirements (large scale fermenters) Complex technical capabilities, difficulties in scaling up operations and
Slide 29: Key Growth Drivers
Key Growth Drivers API Business Expanding API Marketing existing APIs Increasing wallet share Portfolio to new customers with existing customers 01 Formulations Business CONCORD BIOTECH Expanding portfolio through own development & in- Launching new dosage forms including Expanding geographic reach
Slide 30: For further Information, please contact
For further Information, please contact Company: Investor Relations Advisor: Concord Biotech Limited Strategic Growth Advisors Pvt. Ltd. CIN: L24230GJ1984PLC007440 CIN - U74140MH2010PTC204285 Mr. Raviraj Karia – Chief Financial Officer ravirajkaria@concordbiotech.com Mr. Sagar Shroff / Mr. Vatsal Sh